MANNKIND CORP (MNKD)
A
Pipeline Grade
Financial Position (from SEC Filings)
$97.4M
Cash & Equivalents
$5.4M
Quarterly Burn Rate
54 mo
Est. Cash Runway
$1,097M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
INSULIN RECOMBINANT HUMAN
AFREZZA |
APPROVED | Advanced Melanoma, Anal Carcinoma, Asthma, Biliary Tract Cancer, Bone Sarcomas, Breast Carcinoma, Carcinoma of Unknown Origin, Primary, Cervical Carcinoma, Chronic Obstructive Pulmonary Disease (COPD), Colorectal, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Gestational, Diabetes, Type 1, Diabetes, Type 2, Diabetes, Type I, Endometrial Carcinoma, Esophageal Carcinoma, Gallbladder Cancer, Gastric Cancer, Glucose Intolerance During Pregnancy, Glucose Metabolism Disorders, Healthy, Healthy Males, Healthy Subjects, Healthy Volunteers, Idiopathic Pulmonary Fibrosis (IPF), Liver Cancer, MAC Lung Disease, Melanoma, Melanoma (Skin), Mesothelioma, Mild Nephropathy, Moderate Chronic Obstructive Pulmonary Disease, Moderate Nephropathy, Mycobacterium Infections, Nontuberculous, Neuroendocrine Cancer, Ovarian, Pancreatic Carcinoma, Pregnancy Complications, Prostate, Pulmonary Arterial Hypertension, Renal, Small Cell Lung Carcinoma, Soft Tissue Sarcomas, Stage III and IV Mela |
Upcoming Catalysts
No upcoming catalysts detected for this company.